Document is current
Any future updates will be listed below
-
Authors
Baldridge, Abigail S.
Orji, Ikechukwu A.
Shedul, Gabriel L.
Iyer, Guhan
Jamro, Erica L.
Ye, Jiancheng
Akor, Blessing O.
Okpetu, Emmanuel
Osagie, Samuel
Odukwe, Adaora
Dabiri, Haulat Olabisi
Mobisson, L. Nneka
Kandula, Namratha R.
Hirschhorn, Lisa R.
Huffman, Mark D.
Ojji, Dike B.
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (R01HL144708, R01HL144708, R01HL144708, R01HL144708, R01HL144708, R01HL144708, R01HL144708, R01HL144708, R01HL144708, R01HL144708, R01HL144708, R01HL144708, R01HL144708)
Northwestern Bluhm Cardiovascular Institute (NA, NA, NA, NA, NA, NA, NA)
Northwestern Robert J. Havey MD Institute for Global Health (NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA)
Resolve to Save Lives (NA, NA, NA, NA, NA, NA, NA)
- License Information
-
More Information
Article History
Received: 20 December 2023
Accepted: 20 August 2024
First Online: 7 September 2024
Declarations
:
: The study was reviewed and approved by the Ethics Committee at the University of Abuja Teaching Hospital (UATH/HREC/PR/2021/011/015) and the Institutional Review Board at Northwestern University (STU00216041). Ethical oversight of the Nigeria Hypertension Treatment in Nigeria Program was provided by the University of Abuja Teaching Hospital Health Research Ethics Committee, which waived patient informed consent based on the Common Rule. The study was also reviewed by the Federal Capital Territory Ethics Committee and Northwestern University Institutional Review Board. The trial was prospectively registered at under NCT04158154 on November 8, 2019; . This study was performed in accordance with relevant guidelines and regulations in the Declaration of Helsinki.
: Not Applicable.
: MDH has received travel support from the World Heart Federation and consulting fees from PwC Switzerland. MDH has an appointment at The George Institute for Global Health, which has a patent, license, and has received investment funding with intent to commercialize fixed-dose combination therapy through its social enterprise business, George Medicines. MDH has pending patents for heart failure polypills. LRH served as a Guest Editor for ‘The role of community health workers in primary care’ Collection.
